Application of Dps protein nanocages from Listeria monocytogenes in the preparation of drugs for treating sepsis

By efficiently binding Listeria Dps protein nanocages with histones, the application gap of protein nanocages in the treatment of sepsis in existing technologies has been filled, achieving highly effective sepsis treatment without the need for manganese ion activation, thus enhancing the value of biomedical applications.

CN117582487BActive Publication Date: 2026-11-10WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211002857.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-19
Publication Date
2026-11-10
Estimated Expiration
2042-08-19

AI Technical Summary

Technical Problem

There is a lack of effective applications of protein nanocages binding histones in current technologies, especially in the treatment of sepsis, and existing Dps proteins require manganese ion activation to exert their therapeutic effects.

Method used

The study utilizes Dps protein nanocages (LiDps) derived from Listeria monocytogenes. These protein nanocages have a negatively charged outer surface and are naturally polyanionic polymers that can efficiently bind to histones. By binding to histones, the treatment of sepsis is achieved without the need for manganese ion activation.

Benefits of technology

It improved the survival rate of mice in a sepsis model, reduced liver damage, inhibited histone-induced deep vein thrombosis, and demonstrated biocompatibility, providing a novel alternative to extracellular histone antagonist therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the biomedical field, specifically relating to the application of Dps protein nanocages derived from Listeria monocytogenes in the preparation of drugs for treating sepsis. The applicant discovered... Li Dps' highly efficient histone binding ability has been successfully applied in the treatment of inflammatory animal models. In the research... Li Dps has been found to significantly improve the survival rate of mice in a cecum ligation and puncture (CLP) model and alleviate liver damage in the CLP mouse model. This invention further improves the... Li The biomedical applications of protein nanocages, represented by Dps, are also a valuable complement to emerging extracellular histone antagonist therapies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedicine, specifically relating to the application of Dps protein nanocages derived from Listeria monocytogenes in the preparation of drugs for treating sepsis. Background Technology

[0002] Sepsis is a life-threatening organ dysfunction resulting from a dysregulated response to infection [Singer, M.; Deutschman, CS; Seymour, CW; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, GR; Chiche, JD; Coopersmith, CM; Hotchkiss, RS; Levy, MM; Marshall, JC; Martin, GS; Opal, SM; Rubenfeld, GD; van der Poll, T.; Vincent, JL; Angus, DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama-J Am Med Assoc 2016, 315, 801-810.]. In the recent COVID-19 pandemic, COVID-19 infection has frequently induced sepsis in patients, leading to worsening of their condition and even death [Li, H.; Liu, L.; Zhang, DY; Xu, JY; Dai, HP; Tang, N.; Su, X.; Cao, B. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020, 395, 1517-1520.]. Extracellular histones are recently discovered important target molecules for sepsis treatment [Alhamdi, Y.; Toh, CH. The role of extracellular histones in haematological disorders. Br J Haematol 2016, 173, 805-811., Ginsburg, I.; Koren, E. Are histones real pathogenic agents in sepsis? Nat Rev Immunol 2018, 18, 148.]. Histones in the cell nucleus are important components of nuclear chromatin and are considered harmless.However, during the disease process, histones can be released extracellularly, either alone or as DNA-bound nucleosomes or as part of neutrophil extracellular traps (NETs), through different cell death mechanisms such as NETosis, necroptosis, pyroptosis, and ferroptosis [Silk, E.; Zhao, HL; Weng, H.; Ma, DQ. The role of extracellular histone in organ injury. Cell Death Dis 2017, 8., Allam, R.; Kumar, SVR; Darisipudi, MN; Anders, HJ. Extracellular histones in tissue injury and inflammation. J Mol Med 2014, 92, 465-472.]. The released histones exert toxic effects on the body and enhance immune stimulation through cytotoxicity caused by their strong positive charge, activation of Toll-like receptor molecules TLR2 / -4 / (-9), promotion of platelet aggregation and coagulation, activation of inflammasomes, and protection of extracellular DNA from degradation, thus promoting further disease progression. Figure 1[Allam, R.; Kumar, SVR; Darisipudi, MN; Anders, HJ. Extracellular histones in tissue injury and inflammation. J Mol Med 2014, 92, 465-472.]. In 2009, Xu et al. first published an article in Nature Medicine stating that the main cause of death from sepsis is the release of cytotoxic histones outside the cells [Xu, J.; Zhang, XM; Pelayo, R.; Monestier, M.; Ammollo, CT; Semeraro, F.; Taylor, FB; Esmon, NL; Lupu, F.; Esmon, CT. Extracellular histones are major mediators of death in sepsis. Nat Med 2009, 15, 1318-U1117.]. Studies have shown that the release of extracellular histones can lead to endothelial cell dysfunction, organ failure, and death [Xu, J.; Zhang, XM; Pelayo, R.; Monestier, M.; Ammollo, CT; Semeraro, F.; Taylor, FB; Esmon, NL; Lupu, F.; Esmon, CT. Extracellular histones are major mediators of death in sepsis. Nat Med 2009, 15, 1318-U1117., Ostrowski, SR; Berg, RMG; Windelo, NA; Meyer, MAS; Plovsing, RR; Moller, K.; Johansson, Picoagulopathy, catecholamines, and biomarkers of endothelial damage in experimental human endotoxemia and inpatients with severe sepsis: A prospective study. J Crit. Care2013,28,586-596.,Abrams,ST;Zhang,N.;Manson,J.;Liu,TT;Dart,C.;Baluwa,F.;Wang,SS;Brohi,K.;Kipar,A.;Yu,WP;Wang,GZ;Toh,CHCirculating Histones Are Mediators of Trauma-associated Lung Injury. Am J Resp Crit Care2013,187,160-169.]. Extracellular histones are believed to be released in large quantities during disease development and further promote disease progression [Silk, E.; Zhao, HL; Weng, H.; Ma, DQ. The role of extracellular histone in organ injury. Cell Death Dis 2017, 8.], liver [Yang, RK; Zou, XP; Tenhunen, J.; Tonnessen, TIH MGB1 and Extracellular Histones Significantly Contribute to Systemic Inflammation and Multiple Organ Failure in Acute Liver Failure. Mediat Inflamm 2017, 2017., Wen, ZM; Lei, Z.; Yao, L.; Jiang, P.; Gu, T.; Ren, F.; Liu, Y.; Gou, CY; Li, XH; Wen, T. Circulating histones are major mediators of systemic inflammation and cellular injury in patients with acute liver failure. Cell Death Dis2016,7.,Huang,H.;Evankovich,J.;Yan,W.;Nace,G.;Zhang,LM;Ross,M.;Liao,XH;Billiar,T.;Xu,J.;Esmon,CT;Tsung,A. 9inMice.Hepatology2011,54,999-1008.]﹑Kidney [Allam, R.; Scherbaum, CR; Darisipudi, MN; Mulay, SR; Hagele, H.; Lichtnekert, J.; Hagemann, J.H., Rupanagudi, K.V., Ryu, M., Schwarzenberger, C., Hohenstein, B., Hugo, C., Uhl, B., Reichel, CA, Krombach, F., Monestier, M., Liapis, H., Moreth, K., Schaefer, L., Anders, H.J. Histones from DyingRenal Cells Aggravate Kidney Injury via TLR2 and TLR4.J Am Soc Nephrol2012,23,1375-1388.]﹑Lungs [Zhang, HB; Villar, J.; Slutsky, ASCirculating Histones: Novel Target in Acute Respiratory Distress Syndrome? Am J Resp Crit Care 2013, 187, 118-120., Ward, PA; Graier, J J Acute lung injury and the role of histones. Transl Respir Med 2014, 2, 1.] and damage to organs such as the heart [Kalbitz, M.; Graier, JJ; Fattahi, F.; Jajou, L.; Herron, TJ; Campbell, KF; Zetoune, FS; Bosmann, M.; Sarma, JV; Huber-Lang, M.; Gebhard, F.; Loaiza, R.; Valdivia, HH; Jalife, J.; Russell, MW; Ward, PARole of extracellular histones in the cardiomyopathy of sepsis. FASEBJ 2015, 29, 2185-2193.] is closely related to extracellular histones. These provide a theoretical basis for histone antagonist therapy. Antagonists that bind to histones, such as heparin, include non-agglutinating heparin [Semeraro, F.; Ammollo, CT; Morrissey, JH; Dale, GL; Friese, P.; Esmon, NL; Esmon, CT].Extracellular histones promote thrombin generation through platelet-dependent mechanisms:involvement of platelet TLR2 and TLR4.Blood2011,118,1952-1961.,Wildhagen,KCAADe Frutos,PG;Reutelingsperger,CP;Schrijver,R.Areste,C.Ortega-Gomez,A.Deckers,NM;Hemker,HCSoehnlein,O.Nicolaes,GAFNonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis.Blood2014,123,1098-1101.,Fuchs,TA;Brill,A.Duerschmied,D.Schatzberg,D.;M onestier,M.Myers,DDWrobleski,SKWakefield,TWHartwig,JHWagner,DDExtracellular DNA traps promotethrombosis.P Natl Acad Sci USA2010,107,15880-15885.] [Nakahara,M.;Ito,T.]Kaw ahara,K.;Yamamoto,M.;Nagasato,T.;Shrestha,B.;Yamada,S.;Mi Yauchi,T.Higuchi,K.Takenaka,T.Yasuda,T.Matsunaga,A.Kakihana,Y.Hashiguchi,T.Kanmura,Y.Maruyama,I.Recombinant Thrombomodulin Protects Miceagainst Histone-Induced Lethal Thromboembolism.Plos One2013,8.]、Advanced BWA3[Xu,J.1Zhang,XM1Pelayo,R.1Monestier,M.1Ammollo,CT;Semeraro,F.;Taylor,F.B.;Esmon,N.L.;Lupu,F.;Esmon,C.T.Extracellular histones are major mediatorsof death in sepsis.Nat Med2009,15,1318-U1117.,Allam,R.;Scherbaum,C.R.;Darisipudi,M.N.;Mulay,S.R.;Hagele,H.;Lichtnekert,J.;Hagemann,J.H.;Rupanagudi,K.V.;Ryu,M.;Schwarzenberger,C.;Hohenstein,B.;Hugo,C.;Uhl,B.;Reichel,C.A.;Krombach,F.;Monestier,M.;Liapis,H.;Moreth,K.;Schaefer,L.;Anders,H.J.Histonesfrom Dying Renal Cells Aggravate Kidney Injury via TLR2 and TLR4.J Am SocNephrol2012,23,1375-1388.,Xu,J.;Zhang,X.M.;Monestier,M.;Esmon,N.L.;Esmon,C.T.Extracellular Histones Are Mediators of Death through TLR2 and TLR4 inMouse Fatal Liver Injury.J Immunol2011,187,2626-2631.,De Meyer,S.F.;Suidan,G.L.;Fuchs,T.A.;Monestier,M.;Wagner,D.D.Extracellular Chromatin Is anImportant Mediator of Ischemic Stroke in Mice.Arterioscl Throm Vas2012,32,1884-U1394.,Caudrillier,A.;Kessenbrock,K.;Gilliss,B.M.;Nguyen,J.X.;Marques,M.B.;Monestier,M.;Toy,P.;Werb,Z.;Looney,M.R.Platelets induce neutrophilextracellular traps in transfusion-related acute lung injury.J ClinInvest 2012, 122, 2661-2671.] and polyanions [O'Meara, CH; Coupland, LA; Kordbacheh, F.; Quah, BJC; Chang, CW; Davis, DAS; Bezos, A.; Browne, AM; Freeman ,C.;Hammill,DJ;Chopra,P.;Pipa,G.;Madge,PD;Gallant,E.;Segovis,C.;Dulhunty,AF;Arnolda,LF;Mitchell,I.;Khachigian,LM;Stephens,RW;von Itzstein,M.;Parish,CRNeutralizing the pathological effects of extracellular histoneswith small polyanions.Nat [Common 2020, 11.] et al. have shown that histone-related pathological processes are inhibited by neutralizing histone toxicity and suppressing histone-related thrombosis and coagulation.

[0003] Protein nanocages are three-dimensional shell-like nanomaterials with highly symmetrical structures assembled from multiple protein subunits. They are characterized by low biotoxicity, good biocompatibility, ease of modification, ease of preparation, high yield, and suitability for large-scale production, thus possessing great value for medical applications.

[0004] However, there are currently no publicly available reports on protein nanocages binding histones, nor are there any applications of protein nanocages in the treatment of sepsis through histone binding. Dps proteins (DNA-binding proteins from starved cells) are a type of 12-mer protein nanocage with an outer diameter of 9 nm and an inner lumen of 5 nm. They possess stress resistance, can bind metal ions, and have antioxidant properties [Chiancone, E.; Ceci, P. The multifaceted capacity of Dps proteins to combat bacterial stress conditions: Detoxification of iron and hydrogen peroxide and DNA binding. Bba-Gen Subjects 2010, 1800, 798-805.].

[0005] Currently, among Dps proteins, only SsDps from *Sulfolobus solfataricus* has been reported to treat sepsis [Uchida, M.; Maier, B.; Waghwani, HK; Selivanovitch, E.; Pay, SL; Avera, J.; Yun, EJ; Sandoval, RM; Molitoris, BA; Zollman, A.; Douglas, T.; Hato, T. The archaeal Dps nanocage targets kidney proximal tubules via glomerular filtration. *J Clin Invest* 2019, 129, 3941-3951.]. In this study, SsDps was found to treat endotoxin (LPS)-induced kidney injury through antioxidant action. Notably, SsDps requires additional manganese ion activation to exert its therapeutic effect. Summary of the Invention

[0006] The purpose of this invention is to apply Dps protein nanocages derived from Listeria monocytogenes in the preparation of drugs for treating sepsis.

[0007] To achieve the above objectives, the present invention adopts the following technical measures:

[0008] The applicant discovered that Dps protein nanocages derived from Listeria can treat sepsis without the need for manganese ion activation, and that the therapeutic effect is achieved by binding to histones. Therefore, Dps protein nanocages derived from Listeria can be used to prepare drugs for the treatment of sepsis.

[0009] In the above-described applications, preferably, the Dps protein is shown in SEQ ID NO.2.

[0010] The applicant further discovered that the protein nanocages with negatively charged outer surfaces are natural polyanionic polymers that have the potential to bind to histones and thus treat sepsis. Therefore, the properties of these protein nanocages provide another possibility for the screening of drugs for the treatment of sepsis in the future.

[0011] The present invention has the following advantages and effects compared with the prior art:

[0012] Many protein nanocages have negatively charged outer surfaces, making them natural polyanionic polymers. However, there are currently no publicly available reports of protein nanocages binding histones, nor are there any applications of protein nanocages for disease treatment through histone binding. The applicant discovered the highly efficient histone-binding ability of LiDps and successfully applied it to the treatment of inflammatory animal models. In the study, LiDps was found to significantly improve the survival rate of mice in a cecum ligation and puncture (CLP) model and alleviate liver damage in CLP mouse models, and this therapeutic effect did not require manganese ion activation.

[0013] Therefore, protein nanocages, a large class of bionanomaterials, have the potential for therapeutic applications through histone binding. Considering the low biotoxicity, good biocompatibility, ease of modification, ease of preparation, high yield, and suitability for large-scale production of protein nanocages, this invention further enhances the biomedical application value of protein nanocages represented by LiDps, and is also a beneficial supplement to the emerging extracellular histone antagonistic therapy. Attached Figure Description

[0014] Figure 1 This diagram illustrates the characterization of the zeta potential of wtDps and the binding kinetics analysis of the interaction between wtDps and histones.

[0015] Figure 2 Transmission electron microscope images of wtDps, wtDps-CRPPR, and G104C-PEG1000 after negative staining with phosphotungstic acid.

[0016] Figure 3 This is a schematic diagram of gel electrophoresis characterization of modified and unmodified LiDps.

[0017] Where: a is a schematic diagram of agarose gel electrophoresis characterization;

[0018] b shows the SDS-PAGE analysis of the residual protein in the supernatant after incubating different materials (modified and unmodified LiDps) with the same concentration of histones, centrifuging to remove the precipitate, and c shows the concentration analysis.

[0019] Figure 4 This study analyzes the survival curves of different materials at the same concentration in a CLP mouse model after treatment.

[0020] Figure 5 This study aims to analyze the liver protective effect of wtDps on a CLP mouse model.

[0021] Figures a and b show a comparison of ALT and AST in blood; figure c shows a typical liver pathological section analysis.

[0022] Figure 6 The distribution of wtDps in the CLP mouse model.

[0023] Figure 7 The results show plasma histone content (a) and the interaction between wtDps and nucleosome (b).

[0024] Figure 8 The therapeutic effect of wtDps on histone-induced mice;

[0025] Where: a: survival curve analysis; b: blood lactate dehydrogenase analysis.

[0026] Figure 9 Analysis of thrombosis inhibition of wtDps in a histone-induced deep vein thrombosis model;

[0027] Where a: separated thrombus; b: thrombus weight analysis; c: thrombus length analysis).

[0028] Figure 10a This is a schematic diagram illustrating wtDps' inhibition of histone-induced platelet aggregation.

[0029] Figure 10b This is a schematic diagram illustrating how wtDps inhibits histone-induced erythrocyte aggregation.

[0030] Figure 10c This is a schematic diagram illustrating the inhibition of histone toxicity on erythrocytes by wtDps.

[0031] Figure 11 Biosafety analysis of wtDps;

[0032] Wherein, a: cytotoxicity; b: mouse survival rate and weight change; c: pathological section analysis. Detailed Implementation

[0033] Unless otherwise specified, the technical solutions described in this invention are all conventional technologies in the field; unless otherwise specified, the reagents or materials described are all from commercial sources.

[0034] Example 1:

[0035] Protein nanocages with negatively charged outer surfaces can bind to histones:

[0036] 1) Obtaining LiDps protein nanocages

[0037] LiDps are Dps proteins (DNA-binding proteins from starved cells) derived from Listeria innocua. They are protein nanocages formed by 12-mers. Unmodified LiDps (wtDps, wild-type LiDps) have a negatively charged outer surface (pI = 4.75, zeta potential = -32.7 ± 5.5 mV). Figure 1 LiDps, being a naturally occurring polyanion, is therefore likely to bind to positively charged histones. The applicant discovered that LiDps exhibits extremely high affinity (K-type) for histones. D =27.9pM ( Figure 1 b) Furthermore, LiDps bind to histones to form a significant precipitation complex. Therefore, LiDps is a highly efficient histone-binding material.

[0038] Using the wtDps gene sequence (SEQ ID NO.1, encoding the protein shown in SEQ ID NO.2) as a template, PCR amplification was performed (upstream primer 5-CCCCCCCATATGAAAACAATCAACTCAGTAGAC-3, downstream primer 5-TTTCTCGAGTTATTCTAATGGAGCTTTTCCAAGGA-3). The wtDps gene, with NdeI and Xho I introduced upstream and downstream, was ligated into pET32a and then transformed into *E. coli* for expression. After amplification culture, 1 mM IPTG was added, and expression was induced at 160 rpm / min and 25℃ for approximately 12 h. Cells were then collected. The cells were resuspended in Tris-HCl buffer (pH 8.0), sonicated, and the supernatant was collected by centrifugation. DNase was added, and the DNA was removed by incubation at room temperature. The cells were then treated at 60℃ for 10 min, and the supernatant was collected by centrifugation. Protein precipitates with 50%-90% ammonium sulfate saturation were collected by ammonium sulfate precipitation. The protein precipitates were resuspended, dialyzed, and then loaded onto a HiTrap Q HP column (GE). Healthcare uses the AkaTa protein purification instrument to adjust the salt ion concentration of the elution buffer by controlling the ratio of buffer A (20 mM Tris-HCl, pH 7.4) and B (20 mM Tris-HCl, 1 M NaCl, pH 7.4) to obtain wtDps.

[0039] 2) The binding affinity of protein nanocages to histones is related to the charge they carry.

[0040] By fusing targeting peptides or modifying the outer surface of LiDps with polyethylene glycol (PEG) to shield the negative charge on the outer surface of Dps, we constructed wtDps-CRPPR (with GGGGSGGGGS linker peptide and CRPPR targeting peptide fused to the C-terminus of wtDps, pI = 4.96) and G104C-PEG1000 (the glycine at position 104 of wtDps is mutated to cysteine, and PEG1000 is modified via a highly efficient thiol-maleimide click reaction). Although transmission electron microscopy showed that the modified LiDps proteins had a cage-like structure similar to wtDps (… Figure 2 However, agarose gel electrophoresis analysis showed that wtDps-CRPPR and G104C-PEG1000 carried a lower negative charge than wtDps. Figure 3 (a) Simultaneously, utilizing the property of LiDps binding to histones to form insoluble precipitates, the supernatant after LiDps binding to histones was analyzed using SDS-PAGE and protein concentration assays, demonstrating that the binding ability of the modified LiDps to histones was significantly reduced compared to wtDps. Figure 3(b, c). Therefore, we conclude that the histone binding ability of LiDps is correlated with the charge on the outer surface of its protein nanocage.

[0041] Example 2:

[0042] Application of negatively charged protein nanocages on their outer surface in the preparation of drugs for treating sepsis:

[0043] The experimental procedure, using a sepsis model with cecal ligation and perforation (CLP) as an example, is as follows:

[0044] 1) Seven- to eight-week-old male C57BL / 6J mice were randomly divided into three groups: surgical treatment group (CLP+wtDps group, CLP+wtDps-CRPPR group, CLP+G104C-PEG1000 group), surgical control group (CLP+PBS group), and non-surgical control group (PBS group), with eight mice in each group. The mice were allowed to acclimatize to the environment for 2 to 3 days before the formal experiment.

[0045] 2) Administer azithromycin intraperitoneally (240 mg / kg body weight). After anesthesia, cover the surgical area with skin. Preoperative disinfection: Fix the animal on a warming mat and gently disinfect the surgical area three times with 75% alcohol swabs. Surgical procedure: Using surgical scissors, make longitudinal incisions layer by layer through the skin and abdominal muscle layers 0.3 cm below the midpoint of the linea alba, with an incision length of approximately 1.5 cm. Use flat forceps with the left hand to grasp the muscle layer and explore the abdominal cavity under direct vision. Use flat forceps with the right hand to pull out the distal end of the cecum and place it outside the abdominal wall. Ligate the cecum at 50% using 5 / 0 surgical sutures. After ligation, use a 16-gauge needle to vertically puncture twice, avoiding blood vessels. After squeezing out a small amount of feces, return the cecum to the abdominal cavity. The abdominal wall muscles and abdominal skin were sutured with 5 / 0 surgical sutures. Postoperative fluid resuscitation: physiological saline (50 ml / kg body weight) was injected subcutaneously into the neck and back after surgery. Then, the CLP+wtDps group was injected with 24 mg / kg wtDps, while other surgical treatment groups and surgical control groups were injected with the same concentration of protein or the same volume of PBS. This time was counted as 0 h. The mice were placed on a warming pad to wait for awakening. After awakening, they were put back into the cage and given water and feed. The second injection was given 11 h later. The injection material and content were exactly the same as the first injection.

[0046] 3) Observe and record the condition of the mice every day, change and add bedding, water and food regularly, and remove dead mice in a timely manner until the experiment is completed.

[0047] 4) Based on the statistical results, draw the survival rate curve.

[0048] Experimental results:

[0049] Based on the survival rate curves, it was found that all of the aforementioned LiDps materials significantly improved the survival rate of the sepsis model. Furthermore, the mice in the wtDps treatment group showed the highest survival rate, reaching 87.5% at 28 days. Figure 4 The above results demonstrate that LiDps has a therapeutic effect on sepsis and provide evidence for the correlation between therapeutic effect and histone binding ability.

[0050] Next, we used the wtDps treatment group as a representative and compared it with the unoperated group (PBS group) and the surgical untreated group (CLP+PBS group) (Note: the CLP surgical method is the same as above). Through blood biochemistry analysis and pathological section analysis, we found that wtDps can effectively treat liver damage in the CLP model. Figure 5 In addition, wtDps modified with the near-infrared fluorescent molecule AlexaFluor750 were injected into CLP mice. After dissection at different time points (three replicates per time point), organ distribution was analyzed by small animal imaging. The results showed that wtDps were most abundant in the liver of CLP mice, and a large amount of wtDps was still present in the liver at 5 days. Figure 6 This further supports the efficacy of wtDps in treating liver injury caused by CLP. Furthermore, through antibody immunoassay, we found a significant increase in histone concentration in the blood of CLP-operated mice compared to unoperated mice. Figure 7 (a) Because histones released into the bloodstream, besides existing in their individual forms, often form complexes with other biomolecules such as nucleosomes and NETs. Among these complexes, nucleosomes contain a high concentration of histones; therefore, we investigated the interaction between wtDps and nucleosomes. Fluorescence detection experiments confirmed the interaction between wtDps and nucleosomes. Figure 7 (b)

[0051] Example 3:

[0052] Histone-induced animal models and histone-induced deep vein thrombosis (DVT) models.

[0053] The experimental procedure for histone-induced animal models is as follows:

[0054] 1) Five-week-old female BALB / c mice were randomly divided into four groups: a low-concentration histone treatment group (Low HTs + wtDps group), a low-concentration histone control group (Low HTs + PBS group), a high-concentration histone treatment group (High HTs + wtDps group), a high-concentration histone control group (High HTs + PBS group), and a negative control group (PBS group), with eight mice in each group. Mice were allowed 2–3 days to acclimatize to the environment before the formal experiment.

[0055] 2) In the Low HTs+wtDps and High HTs+wtDps groups, 50 mg / kg of wtDps was injected, while in other groups, the same volume of PBS was used instead. Ten minutes after injection, 45 mg / kg of histone (in the Low HTs+wtDps and Low HTs+PBS groups) or 63 mg / kg of histone (in the High HTs+wtDps and High HTs+PBS groups) was injected, while in the PBS groups, the same volume of PBS was used instead.

[0056] 3) After administration, continue to observe and record the condition of the mice daily, change and add bedding, water and food regularly, and remove dead mice in a timely manner until the experiment is completed.

[0057] 4) Based on the statistical results, plot the weight change curve and the survival rate curve.

[0058] Experimental results:

[0059] According to the survival curves, the survival rate of mice in the High HTs+wtDps group was higher than that in the High HTs+PBS group, and the survival rate of mice in the Low HTs+wtDps group was higher than that in the Low HTs+PBS group; at the same time, the survival rate curves of the High HTs+wtDps group were statistically significant compared with those of the High HTs+PBS group. Figure 8 The above results demonstrate that wtDps can treat histone-induced animal models.

[0060] The experimental procedure for the histone-induced deep vein thrombosis (DVT) model is as follows:

[0061] 1) Seven- to eight-week-old C57BL / 6J mice were randomly divided into a drug treatment group (DVT+wtDps group) and a control group (DVT+PBS group);

[0062] 2) Administer azithromycin intraperitoneally (240 mg / kg body weight). After anesthesia, cover the surgical area with skin. Preoperative disinfection: Fix the animal on a warming mat and gently disinfect the surgical area three times with 75% alcohol swabs. Surgical procedure: Using surgical scissors, make longitudinal incisions layer by layer along the linea alba, cutting through the skin and abdominal muscle layers. The incision extends from exposing a corner of the liver to the coagulation gland. Use flat forceps with the left hand to grasp the muscle layer, and use flat forceps with the right hand to gently pull out organs such as the small intestine and place them outside the abdominal wall, fully exposing the inferior vena cava. Cover the pulled-out organs with gauze soaked in physiological saline to avoid prolonged exposure to air and dehydration. Use ophthalmic forceps to bluntly dissect the connective tissue around the blood vessels to locate the inferior vena cava and its branches. Carefully separate the abdominal aorta and inferior vena cava below the renal vein. After ligating the inferior vena cava with 7 / 0 surgical sutures, the pulled-out intestines and other organs were carefully returned to the abdominal cavity, and the abdominal wall muscles and abdominal skin were sutured with 5 / 0 surgical sutures. Postoperative fluid resuscitation: physiological saline (50 ml / kg body weight) was injected subcutaneously into the neck and back after surgery, and the mice were placed on a warming pad to wait for awakening; then, histone 10 mg / kg was injected; 4 minutes later, 50 mg / kg wtDps or the same volume of PBS were injected respectively.

[0063] After 24 hours, the surviving mice in the DVT+wtDps group and the DVT+PBS group were sacrificed, and the thrombus in the blood vessel wall was removed. The length and weight of the obtained thrombus were photographed and recorded for statistical analysis.

[0064] Experimental results

[0065] According to statistical analysis, the length and weight of the thrombi separated in the DVT+wtDps group were significantly lower than those in the DVT+PBS group. Figure 9 The above results indicate that wtDps can inhibit thrombus formation in a histone-induced deep vein thrombosis (DVT) model.

[0066] Given that LiDps can improve thrombosis caused by histone-induced coagulation dysfunction, we isolated platelets and erythrocytes from the blood for further study. By analyzing changes in FSC (forward scatter) parameters in flow cytometry to determine cell size changes, we found that LiDps can inhibit histone-induced platelet and erythrocyte aggregation. Furthermore, scanning electron microscopy further demonstrated that LiDps can neutralize the toxicity of histones to erythrocytes. Figure 10a , Figure 10b , Figure 10c The above experimental results demonstrate that LiDps has a therapeutic effect on sepsis. Furthermore, the therapeutic effect of LiDps is closely related to its binding ability with histones, which can neutralize histone toxicity and inhibit histone-induced thrombosis.

[0067] Example 4:

[0068] The cytotoxicity of wtDps was detected at both cellular and in vivo levels:

[0069] (1) Experimental procedures at the cellular level:

[0070] FL83B, RAW264.7, and HFF-1 were respectively calculated according to 1*10 5 / ml, 150μl / well; after incubation at 37°C for 24h, the culture medium was aspirated and fresh culture medium containing a final concentration of 0-480μg / ml wtDps was added and the cells were incubated for another 24h. Each concentration was repeated in 8 replicates. Cell viability was then analyzed using a CCK8 toxicity kit and a microplate reader at 450nm.

[0071] Experimental results

[0072] The addition of wtDps did not show significant cytotoxicity compared to the control group without wtDps.

[0073] (2) Experimental procedures at the animal level:

[0074] 1) Seven- to eight-week-old C57BL / 6J mice were randomly divided into PBS group, 1X wtDps group and 10X wtDps group; the 1X wtDps group was injected with 24 mg / kg wtDps at 0h and 11h, the 10X wtDps group was injected with 240 mg / kg wtDps at 0h and 11h, and the PBS group was injected with the same volume of PBS at 0h and 11h.

[0075] 2) After administration, continue to observe and record the condition of the mice daily, and change and add bedding, water and food regularly; at 22 days, weigh the mice, then dissect them and perform pathological section analysis of each organ.

[0076] Experimental results:

[0077] In vivo injection of 1-fold and 10-fold therapeutic doses of wtDps did not cause death, significant weight changes, or significant organ damage in mice. Figure 11 ).

[0078] Based on data from both cellular and in vivo levels, wtDps can be considered a safe and harmless biomaterial. Example 5:

[0079] EcDps, which also have a protein nanocage structure, do not have the function of treating sepsis:

[0080] The experimental procedure, using a sepsis model with cecal ligation and perforation (CLP) as an example, is as follows:

[0081] EcDps are Dps proteins derived from Escherichia coli. Like LiDps, they form a 12-mer protein nanocage structure. Their protein sequence is shown in SEQ ID NO.3, and their isoelectric point is 5.88.

[0082] 1) Nine-week-old male C57BL / 6J mice were randomly divided into a surgical treatment group (CLP+EcDps group) and a surgical control group (CLP+PBS group), with eight mice in each group. The mice were allowed to acclimatize to the environment for 2-3 days before the formal experiment.

[0083] 2) Administer azithromycin intraperitoneally (240 mg / kg body weight). After anesthesia, cover the surgical area with skin. Preoperative disinfection: Fix the animal on a warming mat and gently disinfect the surgical area three times with 75% alcohol swabs. Surgical procedure: Using surgical scissors, make longitudinal incisions layer by layer through the skin and abdominal muscle layers 0.3 cm below the midpoint of the linea alba, with an incision length of approximately 1.5 cm. Use flat forceps with the left hand to grasp the muscle layer and explore the abdominal cavity under direct vision. Use flat forceps with the right hand to pull out the distal end of the cecum and place it outside the abdominal wall. Ligate the cecum at 40% using 5 / 0 surgical sutures. After ligation, use a 16-gauge needle to vertically puncture twice, avoiding blood vessels. After squeezing out a small amount of feces, return the cecum to the abdominal cavity. The abdominal wall muscles and abdominal skin were sutured with 5 / 0 surgical sutures. Postoperative fluid resuscitation: physiological saline (50 ml / kg body weight) was injected subcutaneously into the neck and back after surgery. Then, the CLP+EcDps group was injected with 70 mg / kg EcDps, while the surgical control group was injected with the same volume of PBS. This time was recorded as 0 h. The mice were placed on a warming pad to wait for awakening. After awakening, they were returned to their cages and given water and feed. The second injection was given 15-16 h later. The injection material and content were exactly the same as the first injection.

[0084] 3) Observe and record the mice's condition daily, regularly change and add bedding, water, and food, and promptly remove any dead mice. Statistical analysis should be conducted for 7 consecutive days. Based on the results, calculate the 7-day survival rate of the mice.

[0085] Experimental results

[0086] The 7-day survival rate of CLP+EcDps was found to be 62.5%, which was lower than that of CLP+PBS (75%), indicating that EcDps failed to demonstrate a therapeutic effect in the sepsis model.

Claims

1. The application of Dps protein nanocages derived from Listeria monocytogenes in the preparation of drugs for improving histone-induced coagulation dysfunction leading to thrombosis, wherein the Dps protein is shown in SEQ ID NO.2.

Citation Information

Patent Citations

  • Transmembrane Dps (starvation-induced DNA binding protein) and application

    CN110283251A

  • Application of lipoic acid in preparation of medicine for treating sepsis and / or septic shock

    CN114425051A